摘要
药品不合理使用和高昂的价格不仅会增加患者用药负担,也会增大医保基金支出压力。在我国取消药品政府定价背景下,厘清市场与政府对药品价格形成的作用机制,有利于发挥市场和政府“两只手”作用,建立适应医药市场发展的药品价格形成机制。本文通过对丹麦药品价格形成机制与价格管控措施的深入研究,探讨了市场机制与政府干预在药品价格形成中的协同作用,并提出了实现药价动态管理、完善医药业法律法规、实行药品分类价格管理、运用多样化政策工具等方面的建议。
Abstract
Unreasonable drug use and high drug prices will not only increase the burden on patients, but also increase the pressure on the expenditure of medical insurance funds. In the context of China's liberalization of government pricing of medicines, clarifying the role of the market and the government on the formation of drug prices is conducive to playing the joint role of the market and the government, and the establishment of a drug price formation mechanism adapted to the development of the pharmaceutical market. Through an in-depth study of drug price formation mechanisms and price control measures in Denmark, this paper explores the synergism of the market mechanism and the government intervention in drug price formation, and puts forward some suggestions for realizing dynamic management of drug prices, improving laws and regulations for the pharmaceutical industry, implementing classified price management for drugs, and applying diversified policies.
关键词
药品价格 /
价格形成 /
价格管理 /
市场机制 /
政府干预
Key words
drug prices /
price formation /
price regulation /
market mechanism /
government intervention
张欣桐, 胡云鹤, 吕兰婷.
市场机制与政府干预在药品价格形成中的协同作用——来自丹麦的启示[J]. 中国医疗保险. 2024, 0(5): 53-59 https://doi.org/10.19546/j.issn.1674-3830.2024.5.007
Synergies Between the Market Mechanism and Government Intervention in Drug Price Formation——Enlightenment from Denmark[J]. China Health Insurance. 2024, 0(5): 53-59 https://doi.org/10.19546/j.issn.1674-3830.2024.5.007
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] OECD Data.Pharmaceutical spending[EB/OL].[2023-12-02].https://data.oecd.org/healthres/pharmaceutical-spending.htm.
[2] Danish Health Authority.The Danish healthcare system[EB/OL].(2023-06-14)[2024-01-13].https://www.sst.dk/en/english/general-public/the-danish-healthcare-system.
[3] Laegemiddelstyrelsen.Tilskud og priser[EB/OL]//Lægemiddelstyrelsen.(2024-03-01)[2024-05-21].https://laegemiddelstyrelsen.dk/da/tilskud/.
[4] Laegemiddelstyrelsen.Omregning til forbrugerpris[EB/OL]//Lægemiddelstyrelsen.(2024-01-08)[2024-5-21].https://laegemiddelstyrelsen.dk/da/tilskud/priser/omregning-til-forbrugerpris/.
[5] Retsinformation.LBK nr 339 af 15/03/2023, Indenrigs- og Sundhedsministeriet[EB/OL]//Retsinformation.(2023-03-15)[2023-12-07].http://www.retsinformation.dk/eli/lta/2023/339.
[6] AMGROS.3-kvartal[EB/OL].[2023-12-11].https://AMGROS.dk/media/fzwa0hj4/3-kvartal.pdf.
[7] Indenrigs-og-Sundhedsministeriet.Nye aftaler sikrer loft over medicinpriserne[EB/OL].(2023-03-31)[2023-12-10].https://www.ism.dk/nyheder/2023/marts/nye-aftaler-sikrer-loft-over-medicinpriserne-.
[8] Anders Munk-Nielsen.Forsker: Der findes en bedre løsning end referencepriser[EB/OL]//Sundhed.(2019-01-29)[2023-12-11].https://www.altinget.dk/sundhed/artikel/postdoc-referencepriser-loeser-ikke-medicinprisernes-himmelflugt.
[9] Christian Jervelund, BRENØE S, Morten Esketveit Rasmussen.Effekten af parallelimporteret medicin[J].Foreningen for Parallelimportører af Medicin,2022.
[10] Christoffer Miguel Frendesen.Apotekerforening: Prisloft kan sætte en stopper for dansk life science[EB/OL]//Sundhed.(2018-12-13)[2023-12-06].https://www.altinget.dk/sundhed/artikel/apotekerforening-prisloft-kan-saette-en-stopper-for-dansk-life-science.
基金
国家社会科学基金青年项目“社会医疗保险‘新卑斯麦'改革模式的国际比较研究”（18CSH060）
